Ropes & Gray advised Solid Biosciences, a biotechnology company specializing in genetic medicines for neuromuscular and cardiac diseases, in a licensing agreement with Armatus Bio for the development of a treatment for Facioscapulohumeral muscular dystrophy (FSHD). The agreement was announced on March 7.
Under the agreement, Solid Biosciences granted Armatus a non-exclusive worldwide license to use Solid’s AAV-SLB101 for treatment of FSHD and Solid will provide Armatus with certain materials, preclinical data and manufacturing and regulatory expertise to facilitate development in Armatus Bio’s gene therapy research.
Financial terms include an upfront payment to Solid, milestone payments upon certain development and sales achievements and tiered royalties on net sales of any resulting products.
Armatus Bio is developing an RNAi-based therapeutic for FSHD, a genetic neuromuscular disorder resulting in muscle weakness and atrophy.
The Ropes & Gray team included life sciences licensing partner Abigail Gregor.
Attorneys
Stay Up To Date with Ropes & Gray
Ropes & Gray attorneys provide timely analysis on legal developments, court decisions and changes in legislation and regulations.
Stay in the loop with all things Ropes & Gray, and find out more about our people, culture, initiatives and everything that’s happening.
We regularly notify our clients and contacts of significant legal developments, news, webinars and teleconferences that affect their industries.